Scarica l'app Stockscreener
0.7147
13.37%
-0.1103
Dopo l'orario di chiusura:
.72
0.0053
+0.74%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.825
Aprire:
$0.74
Volume 24 ore:
2.88M
Relative Volume:
2.94
Capitalizzazione di mercato:
$92.32M
Reddito:
-
Utile/perdita netta:
$-26.91M
Rapporto P/E:
-3.2486
EPS:
-0.22
Flusso di cassa netto:
$-19.57M
1 W Prestazione:
-8.56%
1M Prestazione:
-10.66%
6M Prestazione:
-13.94%
1 anno Prestazione:
-36.19%
Intervallo 1D:
$0.70
$0.772
Intervallo di 1 settimana:
$0.70
$0.99
Portata 52W:
$0.5526
$1.29
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Nome
Atossa Therapeutics Inc
Settore
Industria
Telefono
206.588.0256
Indirizzo
10202 5TH AVENUE NE, SEATTLE, WA
Confronta ATOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.7147 | 106.57M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-01-26 | Iniziato | Maxim Group | Buy |
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Atossa Therapeutics (ATOS) Highlights Promising (Z)-endoxifen Tr - GuruFocus
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium - Yahoo Finance
Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track - Stocktwits
Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn
Atossa gains on rare pediatric disease status for Duchenne asset - MSN
Atossa Therapeutics, Inc. (ATOS) -6.4% in After-hours: Shares Slip Amid Routine Trading - Stocks Telegraph
Atossa Therapeutics (ATOS) Stock: Soars 8% as FDA Grants Rare Pediatric Disease Designation for (Z)-Endoxifen (ATOS) - parameter.io
Why Are Shares Of Atossa Therapeutics Up Today? - Benzinga
Atossa Therapeutics (ATOS) Surges on FDA Pediatric Designation - GuruFocus
Atossa gains on Rare Pediatric Disease status for Duchenne asset - Seeking Alpha
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status - Investing.com UK
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status By Investing.com - Investing.com Nigeria
Atossa Therapeutics (ATOS) Gains FDA Recognition for Duchenne Mu - GuruFocus
Atossa Therapeutics (NASDAQ: ATOS) gets FDA RPD tag; PRVs fetch $100–$160 million - Stock Titan
Adversity is less terrifying than hope: Atossa Therapeutics Inc (ATOS) - setenews.com
Atossa Therapeutics Announces Issuance of U.S. Patent Covering E - GuruFocus
ATOS Receives New Patent for Endoxifen Formulations - GuruFocus
Atossa Therapeutics receives US patent for endoxifen formulations - Investing.com
Atossa Therapeutics (Nasdaq: ATOS) lands U.S. patent with 100 (Z)-endoxifen claims - Stock Titan
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen - Sahm
Ascendiant Capital raises Atossa Genetics stock price target to $8 from $7.75 - Investing.com Canada
Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Genetics (NASDAQ:ATOS) Stock - MarketBeat
Ascendiant Capital Maintains Atossa Therapeutics (ATOS) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for Atossa Therapeutics (ATOS) | ATOS Stock News - GuruFocus
CapEx per share of Atossa Therapeutics, Inc. – BER:YAG2 - TradingView
Analysts Set Atossa Genetics Inc. (NASDAQ:ATOS) Price Target at $6.25 - Defense World
Contrasting Vaso (OTCMKTS:VASO) and Atossa Genetics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback By Investing.com - Investing.com South Africa
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback - Investing.com Canada
Is Atossa Therapeutics Inc. stock undervalued vs historical averagesIPO Watch & Weekly Market Pulse Alerts - Newser
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum - Finviz
Will Atossa Therapeutics Inc. stock outperform tech sector in 2025July 2025 Recap & Safe Capital Investment Plans - Newser
Is Atossa Therapeutics Inc. (YAG2) stock a buy before new product rolloutQuarterly Portfolio Report & Fast Momentum Entry Tips - Newser
Atossa completes FDA meeting on regulatory strategies - MSN
Atossa Completes FDA Meeting on Regulatory Strategies - TipRanks
Atossa Therapeutics Completes FDA Meeting on (Z)-Endoxifen Strategy - TradingView — Track All Markets
Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of "Hold" by Analysts - MarketBeat
Is Atossa Therapeutics Inc. (YAG2) stock considered safe havenJuly 2025 Intraday Action & AI Driven Stock Movement Reports - Newser
Is Atossa Therapeutics Inc. (YAG2) stock good for long term investingWeekly Investment Summary & Low Risk Entry Point Guides - Newser
Will Atossa Therapeutics Inc. stock beat EPS estimates2025 Key Highlights & High Return Stock Watch Alerts - Newser
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma - Lelezard
How Atossa Therapeutics Inc. (YAG2) stock performs in easing cyclesWeekly Trend Summary & Risk Controlled Stock Pick Alerts - Newser
Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth? - Sahm
Insilico Medicine and Atossa Therapeutics publish AI-driven study in Nature's Scientific Reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma - EurekAlert!
S P Trends: How buybacks impact ARMOUR Residential REIT Inc stock valuePrice Action & Daily Profit Maximizing Trade Tips - BỘ NỘI VỤ
Atossa Therapeutics (ATOS) Advances Glioblastoma Research with A - GuruFocus
Can Atossa Therapeutics Inc. (YAG2) stock surprise with quarterly results2025 Momentum Check & Fast Gain Stock Tips - Newser
Published on: 2025-12-02 04:01:13 - Newser
Will Atossa Therapeutics Inc. (YAG2) stock hit Wall Street targetsOptions Play & Precise Trade Entry Recommendations - Newser
Atossa (Nasdaq: ATOS) and Insilico map 1,400 GBM genes to (Z)-endoxifen in AI study - Stock Titan
Atossa Therapeutics (ATOS) Stock Analysis Report | Financials & Insights - Benzinga
Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):